Commercial Considerations For Cell And Gene Therapies: Viewpoints From The 2016 ARM Meeting
Executive Summary
There are still many lessons to be learned in commercializing cell and gene therapies. Experts in the industry discussed challenges and best practices at the Alliance for Regenerative Medicine's annual meeting in October.
You may also be interested in...
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
Seven Key Success Factors In Market Opportunity Assessments
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.